methylphenidate has been researched along with Myotonic Dystrophy in 5 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Myotonic Dystrophy: Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with methylphenidate showed a significant change in median scores on the Daytime Sleepiness Scale (-3." | 9.16 | Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. ( Bouchard, JP; Mathieu, J; Puymirat, J, 2012) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 7.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| " Treatment with methylphenidate showed a significant change in median scores on the Daytime Sleepiness Scale (-3." | 5.16 | Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial. ( Bouchard, JP; Mathieu, J; Puymirat, J, 2012) |
| " His progressively worsening excessive daytime sleepiness (EDS) was treated with methylphenidate hydrochloride." | 3.71 | Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy. ( Aizawa, C; Hirata, K; Miyamoto, M; Miyamoto, T; Suga, T; Takekawa, H, 2002) |
| "However, his hypersomnolence could be attributed to a central dysfunction, and during a follow-up period of 3 years, was successfully treated with methylphenidate." | 1.27 | Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant. ( Boogaard, JM; van den Berg, B; van der Meché, FG, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ramon-Duaso, C | 1 |
| Gener, T | 1 |
| Consegal, M | 1 |
| Fernández-Avilés, C | 1 |
| Gallego, JJ | 1 |
| Castarlenas, L | 1 |
| Swanson, MS | 1 |
| de la Torre, R | 1 |
| Maldonado, R | 1 |
| Puig, MV | 1 |
| Robledo, P | 1 |
| Puymirat, J | 1 |
| Bouchard, JP | 1 |
| Mathieu, J | 1 |
| van der Meché, FG | 2 |
| Bogaard, JM | 1 |
| van der Sluys, JC | 1 |
| Schimsheimer, RJ | 1 |
| Ververs, CC | 1 |
| Busch, HF | 1 |
| Miyamoto, T | 1 |
| Miyamoto, M | 1 |
| Suga, T | 1 |
| Aizawa, C | 1 |
| Takekawa, H | 1 |
| Hirata, K | 1 |
| Boogaard, JM | 1 |
| van den Berg, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1[NCT01421992] | Phase 2/Phase 3 | 28 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for methylphenidate and Myotonic Dystrophy
| Article | Year |
|---|---|
Efficacy and tolerability of a 20-mg dose of methylphenidate for the treatment of daytime sleepiness in adult patients with myotonic dystrophy type 1: a 2-center, randomized, double-blind, placebo-controlled, 3-week crossover trial.
Topics: Adult; Aged; Central Nervous System Stimulants; Cross-Over Studies; Disorders of Excessive Somnolenc | 2012 |
4 other studies available for methylphenidate and Myotonic Dystrophy
| Article | Year |
|---|---|
Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.
Topics: Affect; Animals; Brain; Central Nervous System Stimulants; Cognition; Cognitive Dysfunction; Depress | 2019 |
Daytime sleep in myotonic dystrophy is not caused by sleep apnoea.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Methylphenidate; Middle Aged; Myotonic Dystrophy; Pol | 1994 |
Methylphenidate hydrochloride for excessive daytime sleepiness in a patient with myotonic dystrophy.
Topics: Adult; Central Nervous System Stimulants; Disorders of Excessive Somnolence; Evoked Potentials, Audi | 2002 |
Treatment of hypersomnolence in myotonic dystrophy with a CNS stimulant.
Topics: Adult; Disorders of Excessive Somnolence; Humans; Male; Methylphenidate; Myotonic Dystrophy; Respira | 1986 |